"We report to our knowledge the first clinical data on a PI3 kinase plus BTK inhibitor doublet in B cell malignancies. The preliminary efficacy results certainly show a high response rate," said lead investigator Matthew S. Davids, MD, Department of Medical Oncology, Dana-Farber Cancer Institute. "This approach of dual targeting the B cell receptor pathway is potentially a feasible strategy."
As one of the CLL data points in that study, I can confirm that TGR-1202 is working for me with much less toxicity than Idelalisib had for me. The ibrutinib part of the dual attack on B cell signaling has been much tougher for me- bleeding and Afib problems.
Yes, I have been on a reduced dose of Ibrutinib for about six months so I am still in the trial. Tweaking rhythm control meds for the A-fin and no further bleeding problems
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.